Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/13/2003US20030032581 Pharmaceuticals for treating obesity
02/13/2003US20030032580 Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder
02/13/2003US20030032579 Therapeutic use of selective PDE10 inhibitors
02/13/2003US20030032578 Antifungal and antiparasitic compounds
02/13/2003US20030032577 Therapeutic uses for nitric oxide inhibitors
02/13/2003US20030032166 Aortic carboxypeptidase-like protein and nucleic acids encoding same
02/13/2003US20030032097 DNA encoding human vanilloid receptor VR3
02/13/2003US20030032005 Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
02/13/2003US20030032003 Recovering preferential cells from solution; obtain cells, transform with expression vector, express vector, detect reporter molecule, recover cells expressing reporter molecule
02/13/2003US20030031772 Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glyemic index
02/13/2003US20030031757 Using the ferric complex of ethylenediaminetetracetic acid (EDTA) to fortified beverages and powdered beverage mixes to prevent or treat iron-deficiency anemia; superior iron bioavailability and excellent storage stability
02/13/2003US20030031753 Feeding a pet food composition comprising a source of n-6 and n-3 fatty acids, preferably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); antiinflammatory agents; prostaglandin inhibitors
02/13/2003US20030031739 Dietary supplement of an aqueous extract of red vine leaves and carrier; relief of mild-to-moderate leg discomfort; flavonoids; antiinflammatory, -oxidant, -coagulant and -edema properties; hyaluronidase inhibitors
02/13/2003US20030031738 Saponin mixtures and compounds are isolated from the species Acacia victoriae; e.g., glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents
02/13/2003US20030031736 Treating an aqueous suspension of Ginkgo biloba plant material or extract with an oxidizer, extracting the terpene trilactones and separating the organic layer containing the terpene trilactones from the aqueous layer; purification
02/13/2003US20030031734 An extract of highbush blueberry comprising urosolic acid, 3-beta-19-alpha-dihydroxy-urs-12-en-28-oic acid, gallic acid and procatechuric acid; oxidation resistance; antitumor and -carcinogenic agents;
02/13/2003US20030031727 A water-soluble divalent strontium cation in a suitable topical formulation vehicle; preferably, strontium nitrate, strontium chloride and strontium acetate; cosmetics; drugs soaps; detergents; antiallergens
02/13/2003US20030031726 Calcium dietary supplement
02/13/2003US20030031719 Method for preparing submicron particle suspensions
02/13/2003US20030031718 Once-a-day, topical mixture of ketotifen, a chitosan, and a carrier to administer to the eye to treat allergies
02/13/2003US20030031717 Durable multi-component antibiotic formulation for topical use
02/13/2003US20030031713 Extended release oral dosage composition
02/13/2003US20030031712 Opioid agonist /antagonist combinations
02/13/2003US20030031711 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
02/13/2003US20030031710 Process and composition for temporarily suppressing pain
02/13/2003US20030031706 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein
02/13/2003US20030031705 Solid dispersion of a disintegrant in fenofibrate; bioavailability; made by melting the fenofibrate, blending the disintegrant into the melt, and resolidifying the mixture
02/13/2003US20030031704 Liposome composition for delivery of nucleic acid
02/13/2003US20030031702 Teratogenic drug such as isotretinoin and a contraceptive packaged together with a label specifying avoidance of pregnancy while taking the teratogenic drug; unit dosage
02/13/2003US20030031699 Polymer compositions containing bioactive agents and methods for their use
02/13/2003US20030031694 Controlled release particles
02/13/2003US20030031690 Cosmetic composition for preventing and treating acnes containing cryptotanshinone
02/13/2003US20030031684 Growing a culture of a deep rough mutant bacterial strain in a medium, maintaining in stationary phase for > 5hr, harvesting the cells and extracting lipopolysaccharide
02/13/2003US20030031670 Diagnosis and treatment of malignant neoplasms
02/13/2003US20030031659 For the treatment or prevention of a gastrointestinal infection caused by a pathogenic bacteria; for reducing insect and parasite populations in animal manure
02/13/2003US20030031657 Stem cells and their use in transplantation
02/13/2003US20030031644 For therapy of microbial infection in mammal
02/13/2003US20030031639 Hair growth promoter
02/13/2003US20030031630 Methods, pharmaceutical compositions, oral compositions,filters and tobacco products for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
02/13/2003CA2753329A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
02/13/2003CA2468925A1 Platelet adp receptor inhibitors
02/13/2003CA2457100A1 Taste masking composition
02/13/2003CA2456192A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456187A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456177A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy
02/13/2003CA2456173A1 Quinoline derivatives and use thereof as antitumor agents
02/13/2003CA2456096A1 Novel amine derivative having human .beta.-tryptase inhibitory activity and medecine containing the same
02/13/2003CA2456004A1 Process for the preparation of 5-substituted isobenzofurans
02/13/2003CA2456003A1 Regulator of calcineurin
02/13/2003CA2455975A1 Mucin synthesis inhibitors
02/13/2003CA2455969A1 Methods for inhibiting or reversing tau filament formation polymerization
02/13/2003CA2455858A1 Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
02/13/2003CA2455852A1 Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
02/13/2003CA2455843A1 Therapeutic delivery compositions and methods of use thereof
02/13/2003CA2455833A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
02/13/2003CA2455772A1 Substituted isoindoles and their use
02/13/2003CA2455753A1 Novel 2,4-diaminothiazole derivatives
02/13/2003CA2455749A1 Butyric acid derivatives
02/13/2003CA2455728A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
02/13/2003CA2455711A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
02/13/2003CA2455647A1 Enhancing organ maturity in neonates and predicting their duration of intensive care
02/13/2003CA2455567A1 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
02/13/2003CA2455547A1 Use of vitamin e succinate and antiandrogen combination
02/13/2003CA2455520A1 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
02/13/2003CA2455358A1 Invert emulsion containing dhea
02/13/2003CA2455329A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv
02/13/2003CA2455235A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists
02/13/2003CA2455228A1 Antisense modulation of apolipoprotein b expression
02/13/2003CA2455194A1 Vascular endothelial growth factor isoform having anti-angiogenic activity
02/13/2003CA2455179A1 Androgen receptor modulators and methods of use thereof
02/13/2003CA2455100A1 Mediators of hedgehog signaling pathways,compositions and uses related thereto
02/13/2003CA2454945A1 Use of oversulfated polysaccharides as inhibitors of hiv
02/13/2003CA2454937A1 Modulators of notch signalling for use in immunotherapy
02/13/2003CA2454935A1 Method for the nitration of phenolic compounds
02/13/2003CA2454918A1 Ophthalmic composition containing n-acetyl-cysteine for the treatment of dry-eye syndrome
02/13/2003CA2454422A1 Treatment of ocular hypertension and glaucoma
02/13/2003CA2454414A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones
02/13/2003CA2454147A1 Inhibitor of dna methylation
02/13/2003CA2454136A1 5-aminolevulinic acid and esters, in combination with another photosensitizer, as photosensitizing agents in photochemotherapy, and their uses in_treating wounds
02/13/2003CA2453661A1 (-)-olivil as antioxidant
02/13/2003CA2453410A1 Methods for treating prostatitis
02/13/2003CA2453372A1 Methylation resistant vectors
02/13/2003CA2453274A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
02/13/2003CA2452743A1 5-arylsulfonyl indoles having 5-ht6 receptor affinity
02/13/2003CA2452665A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
02/13/2003CA2452529A1 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
02/13/2003CA2452347A1 Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
02/13/2003CA2451855A1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
02/13/2003CA2451288A1 Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
02/13/2003CA2449804A1 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
02/13/2003CA2448235A1 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
02/13/2003CA2417337A1 Novel crystal forms of 9-substituted hypoxanthine derivatives
02/12/2003EP1283260A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
02/12/2003EP1283211A2 L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus
02/12/2003EP1283210A1 Process for preparation of sulfonamide derivatives and crystals thereof
02/12/2003EP1283203A1 Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide
02/12/2003EP1283199A1 Melanin-concentrating hormone antagonist
02/12/2003EP1283059A2 Therapeutic conjugates of toxins and drugs
02/12/2003EP1283058A1 Agents for preventing or ameliorating insulin resistance and/or obesity
02/12/2003EP1283056A1 Medicinal compositions promoting bowel movement
1 ... 5564 5565 5566 5567 5568 5569 5570 5571 5572 5573 5574 5575 5576 5577 5578 5579 5580 5581 5582 5583 5584 ... 7860